Parenthetically, it may be mentioned that these species discrepancies have been utilized by a pharmaceutical company to make a non-fibrillogenic IAPP variant, used for treatment of type 1 and type 2 diabetes. This evidence concerns the gene IAPP and type 2 diabetes mellitus.